Chad Pecot, MD
@chadpecot.bsky.social
📤 44
📥 75
📝 11
Cancer Killer | Engineering RNA medicines to End Cancer | Potentially sarcastic | Honey-badger
pinned post!
Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. We address two major challenges with RNAi therapeutics in cancer: 1) Delivery, delivery, delivery 2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
3 months ago
1
3
0
Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor. We address two major challenges with RNAi therapeutics in cancer: 1) Delivery, delivery, delivery 2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
3 months ago
1
3
0
reposted by
Chad Pecot, MD
Cancer Cell
4 months ago
Online Now: A first-in-class EGFR-directed KRAS G12V selective inhibitor
loading . . .
A first-in-class EGFR-directed KRAS G12V selective inhibitor
Despite KRAS G12V being a common mutation in cancer, no direct inhibitors currently exist. Stanland et al. demonstrate that an EGFR-directed RNAi platform, EFTX-G12V, selectively targets KRAS G12V while sparing wild-type KRAS. EFTX-G12V shows significant anti-tumor effects and provides insights into mutant-selective KRAS targeting and improved therapeutic activity.
http://dlvr.it/TLS48J
0
4
1
you reached the end!!
feeds!
log in
